UK's LivaNova Q1 revenue beats analyst estimates

Livanova

06/05/2026 11:14

Overview

UK medical device maker's Q1 revenue rose 14%, beating analyst expectations

Adjusted EPS for Q1 beat analyst expectations

Company raised full-year 2026 revenue and adjusted EPS guidance

Outlook

LivaNova raises 2026 revenue growth guidance to 7.0%-8.0% on constant-currency basis

Company now expects 2026 adj diluted EPS of $4.20-$4.30

LivaNova maintains 2026 adj free cash flow guidance at $160 mln-$180 mln

Result Drivers

NEUROMODULATION GROWTH - Q1 Neuromodulation revenue rose 9% on reported basis, supported by higher implant volumes and favorable pricing

OSA BUSINESS MILESTONES - Co achieved FDA approval for aura6000 System and published positive OSPREY trial results for Obstructive Sleep Apnea

Company press release: ID:nBw2881kpa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Beat
$362.30 mln
$346.11 mln (9 Analysts)
Q1 Adjusted EPS
Beat
$0.98
$0.90 (10 Analysts)
Q1 EPS
$0.40


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for LivaNova PLC is $80.00, about 38.9% above its May 5 closing price of $57.59

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)